Your session is about to expire
← Back to Search
Radiation + Immunotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial is proposing to treat metastatic non-small cell lung cancer and head/neck squamous cell cancer patients who are already initiating an immune checkpoint inhibitor by delivering a short-course radiation. The objective is to assess six-month progression free survival compared to historical control.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver enzymes are not more than 5 times the normal limit.I have been treated with immune checkpoint inhibitors before.I do not have a serious infection worse than a moderate level.I have no other cancers except for certain skin cancers, in situ cervical cancer, or any cancer I've been free of for 3 years.I haven't had major surgery or significant injury in the last 14 days, or minor non-brain surgery in the last 3 days.My kidney function, measured by creatinine and clearance rate, is within the required range.I have a serious wound, ulcer, or bone fracture that won't heal.I cannot use certain immune therapies due to my uncontrolled health conditions.My cancer is advanced or has spread, and the tumor is at least 1 cm big.I have had chemotherapy, radiotherapy, or surgery before.I am not pregnant or nursing, and if capable of childbearing, I have a recent negative pregnancy test and agree to use birth control during and for 3 months after the study.My last chemotherapy or radiation was over 3 weeks ago.I am eligible for immune therapy as per FDA guidelines.I do not have any serious ongoing illnesses, including heart issues, uncontrolled high blood pressure, recent strokes, or severe infections like HIV.I am a candidate for radiation therapy.I am 18 years old or older.I have not had major surgery in the last 14 days.
- Group 1: Immune Checkpoint Inhibitor + Radiation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people can sign up for this research project?
"That is correct. The clinicaltrials.gov website does show that this trial is looking for 57 patients at a single centre. The listing was created on October 26th, 2017 and last updated on November 10th, 2022."
Are we still enrolling new participants for this research project?
"The online database clinicaltrials.gov reveals that this particular trial is still searching for participants. The listing was first created on October 26th, 2017 and last updated on November 10th, 2022."
Are there any dangers that come with using an Immune checkpoint inhibitor?
"While there is some evidence of its safety, immune checkpoint inhibitor only received a 2 because there is no data supporting efficacy."
Share this study with friends
Copy Link
Messenger